Cwm LLC Purchases 502 Shares of Teleflex Incorporated (NYSE:TFX)

Cwm LLC boosted its position in Teleflex Incorporated (NYSE:TFX) by 80.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,124 shares of the medical technology company’s stock after acquiring an additional 502 shares during the period. Cwm LLC’s holdings in Teleflex were worth $280,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Rafferty Asset Management LLC lifted its holdings in shares of Teleflex by 6.8% in the third quarter. Rafferty Asset Management LLC now owns 4,910 shares of the medical technology company’s stock valued at $964,000 after purchasing an additional 314 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Teleflex by 243.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 22,722 shares of the medical technology company’s stock valued at $5,666,000 after purchasing an additional 16,110 shares in the last quarter. Royal London Asset Management Ltd. increased its position in shares of Teleflex by 4.3% during the third quarter. Royal London Asset Management Ltd. now owns 17,753 shares of the medical technology company’s stock valued at $3,487,000 after acquiring an additional 737 shares during the last quarter. Raymond James & Associates increased its position in shares of Teleflex by 10.5% during the fourth quarter. Raymond James & Associates now owns 126,227 shares of the medical technology company’s stock valued at $31,473,000 after acquiring an additional 11,943 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Teleflex by 8.8% during the fourth quarter. Nordea Investment Management AB now owns 2,964 shares of the medical technology company’s stock valued at $738,000 after acquiring an additional 239 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

Teleflex Trading Up 2.2 %

Shares of TFX opened at $203.01 on Friday. Teleflex Incorporated has a 1-year low of $177.63 and a 1-year high of $262.97. The firm has a market capitalization of $9.56 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 2.03 and a beta of 1.13. The firm’s 50-day moving average price is $217.97 and its 200-day moving average price is $226.02. The company has a current ratio of 2.32, a quick ratio of 1.29 and a debt-to-equity ratio of 0.39.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 2nd. The medical technology company reported $3.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.07 by $0.14. Teleflex had a net margin of 11.98% and a return on equity of 14.98%. The company had revenue of $737.80 million during the quarter, compared to analysts’ expectations of $726.85 million. During the same period last year, the company posted $3.09 EPS. Teleflex’s revenue was up 3.8% on a year-over-year basis. Sell-side analysts anticipate that Teleflex Incorporated will post 13.73 EPS for the current year.

Teleflex Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a $0.34 dividend. The ex-dividend date was Thursday, February 29th. This represents a $1.36 annualized dividend and a yield of 0.67%. Teleflex’s dividend payout ratio (DPR) is presently 18.06%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TFX. Truist Financial decreased their price target on Teleflex from $240.00 to $219.00 and set a “hold” rating for the company in a research report on Friday. Needham & Company LLC reaffirmed a “hold” rating on shares of Teleflex in a research report on Friday. Royal Bank of Canada decreased their price target on Teleflex from $272.00 to $265.00 and set an “outperform” rating for the company in a research report on Friday, February 23rd. JMP Securities reissued a “market outperform” rating and set a $285.00 price objective on shares of Teleflex in a report on Friday, February 23rd. Finally, StockNews.com downgraded Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, February 23rd. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $261.75.

Insiders Place Their Bets

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of Teleflex stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $225.00, for a total value of $1,665,225.00. Following the completion of the transaction, the vice president now directly owns 10,050 shares of the company’s stock, valued at $2,261,250. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.43% of the company’s stock.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.